| HOME >> BIOLOGY >> TECHNOLOGY |
JUPITER, Fla., April 27, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,923,236 entitled, "Fungal Enzymes" by the United States Patent and Trademark Office ("USPTO").
The inventions embodied by this patent relate to the use of and methods for producing novel enzymes and their combinations to convert lignocellulosic biomass into fermentable sugars. These unique enzymes degrade lignocellulosic sugars including those that provide a synergistic release of sugars from plant biomass.
The inventions also relate to methods of using novel enzymes and their combinations in a variety of other processes including the simultaneous production of organic substances such as alcohol, ethanol, amino and organic acids as well as other organic substances. Additional claims are directed to a variety of pulp and paper manufacturing processes such as biorefining, deinking and bleaching as well as for use in the treatment of waste streams and in textile and detergent processes. These enzymes were isolated from Dyadic's patented and proprietary C1 fungus and additionally identified through the genome annotation project conducted by Dyadic in conjunction with Scripps Florida.
Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "This patent provides Dyadic with additional protection in the use of unique enzymes generated from Dyadic's C1 platform technology to unlock the economic power of converting plentiful feedstocks of plant materials into sugars that can be fermented into chemicals, plastics, and fuels including ethanol, as a substitute for petroleum. These novel enzymes may also be applied in other industries in which Dyadic competes such as pulp an
'/>"/>
| SOURCE Dyadic International, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029
2. Cellectis Receives Payment for License to Homologous Recombination Patents
3. ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China
4. Grunenthal Group Acquires Pain Patent Portfolio From Nectid, Inc.
5. ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air
6. ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
7. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
8. Fuisz Pharma Announces Patented Communication of Analyte Information Between Microchip Containing Smart Tablet and a Body Fluid Analyzer
9. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
10. Reportlinker Adds Amphotericin B - Comprehensive patent search
11. Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |